1. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 v1.0. IARC CancerBase No. 11 [Internet]. Lyon (France): International Agency for Research on Cancer; 2017;[cited 2017 Aug 14]. Available from:
http://globocan.iarc.fr
.
2. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234-41.
3. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 2014;311:183-92.
4. Report Caisse nationale de l'assurance maladie. Risque de cancer de la vessie chez les personnes diabe´ tiques traite´ es par pioglitazone en France: une e´ tude de cohorte sur les donne´ es du SNIIRAM et du PMSI. Rapport final du 7/06/2011. Paris (France), Caisse nationale de l'assurance maladie. 2016;
5. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927-34.
6. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-66.
7. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
8. Alison MR. Assessing cellular proliferation: what's worth measuring? Hum Exp Toxicol 1995;14:935-44.
9. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, editors. AJCC cancer staging manual. 6th ed New York: Springer-Verlag; 2002.
10. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
11. Drach J, Gattringer C, Glassl H, Drach D, Huber H. The biological and clinical significance of the KI-67 growth fraction in multiple myeloma. Hematol Oncol 1992;10:125-34.
13. Bai XZ, Masters JR, O'Donoghue N, Kirby R, Pan LX, Young M, et al. Prognostic markers in clinically localised prostate cancer. Int J Oncol 1999;14:785-91.
15. Moul JW, Bettencourt MC, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, et al. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996;120:159-66.
16. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006;12:7369-73.
18. Ding W, Gou Y, Sun C, Xia G, Wang H, Chen Z, et al. Ki-67 is an independent indicator in nonmuscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC. Urol Oncol 2014;32(42):e13-9.